Bleeding Disorders Treatment Market Overview

Bleeding disorders result in susceptibility to bleeding due to faulty blood clotting, caused by defect in the blood coagulation. Bleeding disorders treatment includes the drugs used in the treatment and management of such bleeding disorders. The global Bleeding Disorders Treatment Market Share is continually growing owing to the prevalence of bleeding disorders such as hemophilia, platelet disorders, Von Willebrand disease and others.

According to Market Research Future (MRFR), the global bleeding disorders treatment market is expected to garner a CAGR of over 10.0% over the assessment period. The demographic drivers of the market include the growing incidence of bleeding disorders and the growing population. According to the National Hemophilia Foundation hemophilia affects about 20,000 people in the United States and more than 400,000 people globally. Platelet disorders have an incidence of 1900to 6400 per 10000a year.

The economic driving factors include the growing per capita income and healthcare expenditure as percent of GDP. The psychotropic drivers of the market include the increasing awareness of bleeding disorders. The market is also expected to rise due to growth in the diagnosis rate owing to development of healthcare infrastructure and government initiatives such ascompulsory screening which is complementing the market growth.

Bleeding Disorders Treatment Market Segmentation

·         The global market for bleeding disorders is segmented by type, treatment, class of drugs, and end-users. The type segment, the global market for the treatment of bleeding disorders, is bifurcated into hemophilia B, hemophilia A, von Willebrand disease, and so on.

·         By drug class, the global hemorrhagic disorders market is segmented recombinant coagulation factor concentrate, plasma-derived coagulation factor concentrates, and others. The recombinant coagulation factor concentrate segment is expected to dominate the market due to increased R&D investment in the production and development of recombinant products by the major players in the market.

·         The global bleeding disorders treatment market is diversified into hormone replacement therapy, desmopressin (DDAVP), pipeline analysis, anti-fibrinolytic/clot stabilizing drugs, contraceptives, drugs applied to cuts.

·         By end-user mode, the global market for bleeding disorders is segmented into clinics, hospitals, research institutions, specialist clinics, and others.

Bleeding Disorders Treatment Market Regional Analysis

North America dominates the global bleeding disorders treatment market owing to high cost of treatment, excellent diagnosis rates and reimbursement and compulsory new born screening introduced under the healthcare programme. Government initiatives such as the US National Hemophilia Program (NHP) which is a collaborative effort by Maternal and Child Health Bureau (MCHB) under the auspices of the Health Resources and Services Administration (HRSA), the National Hemophilia Foundation (NHF), and the Centers for Disease Control and Prevention (CDC) is driving a faster market uptake.

The Asia Pacific bleeding disorders treatment market is expected to gain a massive traction owing to large patient pool and the concurrent large potential market. The expanding healthcare infrastructure and diagnostic labs coupled with the availability of affordable test kits and the burgeoning pharma sector is expected to drive a large market value over the study period.

The bleeding disorders treatment market in Europe is dominated by Germany, France, U.K. and the Nordic states. The provisions of tax cuts owing to the approval of rare diseases certificate to many genetic acquired bleeding disorders such as Haemophilia by National Organization for Rare Disorders is driving a large market. The incidence rate of haemophilia in Eu is around 5 per 10 000 people. Establishment of transnational medical bodies such as the European Association for Haemophilia and Allied Disorders (EAHAD), which cares for the provision of care and advancement of rights and welfare of patients suffering from bleeding disorders coupled with greater availability of finance is driving a large market.

Bleeding Disorders Treatment Market Players

·        Shire Plc

·        Pfizer Inc.

·        Bayer Pharmaceuticals

·        Biogen Inc.

·        BDI Pharma

·        CSL Behring

·        Grifols

·        Sun Pharmaceutical Industries Ltd.

·        Octapharma

·        Ferring Pharmaceuticals

·         Novo Nordisk A/S

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/bleeding-disorders-treatment-market-6592

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com